Press releases
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
More ▼
Key statistics
As of last trade Spyre Therapeutics Inc (3920:BER) traded at 34.85, -18.76% below its 52-week high of 42.90, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.80 |
---|---|
High | 34.85 |
Low | 34.80 |
Bid | 33.65 |
Offer | 36.05 |
Previous close | 34.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 40.28m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.52bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of May 17 2024 09:50 BST.
More ▼